Business

Femasys to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and hosted by M-Vest on June 20-22, 2023

ATLANTA, June 14, 2023 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company aiming to meet women's needs by developing a suite of products

articleFemasys Inc.June 14, 20233/company/femasys-inc/news/femasys-to-participate-in-the-healthcare-virtual-conference-presented-by-maxim-group-llc-and-hosted-by-m-vest-on-june-20-22-2023
Femasys to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and hosted by M-Vest on June 20-22, 2023

About this update from Femasys Inc.

[{"type":"text","content":"ATLANTA, June 14, 2023 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company aiming to meet women's needs by developing a suite of products and product candidates that include minimally invasive, in-office technologies for reproductive health, today announced that Kathy Lee-Sepsick, founder, president & chief executive officer, has been invited to present at the Healthcare Virtual Conference Part II, presented by Maxim Group LLC and hosted by M-Vest. The conference is being held virtually on June 20-22, 2023. Kathy Lee-Sepsick will participate in a fireside chat with Jason McCarthy, senior managing director and head of biotechnology research at Maxim Group on June 22 at 9:00am ET. This conference will be live on M-Vest. To attend, sign up to become an M-Vest member and register here. About Femasys Femasys Inc. is a biomedical company aiming to meet women's needs worldwide by developing a suite of products and product candidates that include minimally invasive, in-office technologies for reproductive health. Its two lead product candidates are FemBloc® permanent birth control and FemaSeed® localized directional insemination for infertility. The Company’s products currently marketed in the United States include FemVue® for fallopian tube assessment by ultrasound, which can be used in conjunction with FemCath®, an intrauterine catheter for selective evaluation of the fallopian tubes, and FemCerv®, an endocervical tissue sampler that is the first product of the technology platform for tissue sampling. To learn more, visit www.femasys.com or follow us on Twitter, Facebook, and LinkedIn. Contacts: Investors Chuck PadalaLifeSci Advisors, [email protected] Femasys Inc. Investor Contact:[email protected] Media Contact:[email protected] \nSource: Femasys Inc.","length":4966,"tagName":"div"}]

More updates from Femasys Inc.